Xilio Therapeutics stockholders elect Clancy and Rossi as Class III directors at annual meeting

Xilio Therapeutics, Inc.

Stockholders elected Paul J. Clancy and Christina Rossi as Class III directors each with ~94.4% of votes cast (excluding broker non-votes).
Auditor Ernst & Young ratified with 26,199,617 votes for (99.6% of votes cast).
Broker non-votes of 6,783,293 on director election; none on auditor ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.